Mercados españoles cerrados en 6 hrs 17 min

Novo Nordisk A/S (NOVO-B.CO)

Copenhagen - Copenhagen Precio en tiempo real. Divisa en DKK
Añadir a la lista de favoritos
874,00+2,70 (+0,31%)
A partir del 11:13AM CEST. Mercado abierto.

Novo Nordisk A/S

Novo Alle 1
Bagsvaerd 2880
Denmark
45 44 44 88 88
https://www.novonordisk.com

Sector(es)Healthcare
SectorBiotechnology
Empleados a tiempo completo63.370

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Lars Fruergaard JorgensenPresident, CEO & Member of Management Board32,3MN/A1966
Mr. Karsten Munk KnudsenExecutive VP, CFO & Member of the Management Board12,8MN/A1971
Mr. Henrik Ehlers WulffExecutive VP of Product Supply, Quality & IT and Member of the Management Board12,9MN/A1970
Ms. Camilla SylvestExecutive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board12,6MN/A1972
Dr. Martin Holst LangeExecutive VP of Development & Member of the Management Board12,2MN/A1970
Dr. Marcus Schindler Ph.D.EVP of Research & Early Development, Chief Scientific Officer & Member of the Management Board12,2MN/A1966
Mr. Maziar Mike DoustdarExecutive VP of International Operations & Member of the Management BoardN/AN/A1970
Mr. Douglas J. LangaExecutive VP of North America Operations & Member of Management BoardN/AN/A1966
Mr. Ludovic HelfgottExecutive VP, Head of Rare Disease & Member of Management BoardN/AN/A1974
Ms. Tania SabroeExecutive VP of Global People & Organisation and Member of Management BoardN/AN/A1977
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en DKK.

Descripción

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Gobierno corporativo

El ISS Governance QualityScore de Novo Nordisk A/S, a día 1 de abril de 2024, es 1. Las puntuaciones base son Auditoría: 2; Tablero: 2; Derechos de los accionistas: 9; Compensación: 1.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.